Both studies showed that the iTME in a BRCA1/2-mutated setting had greater frequencies of CD8 T cells, macrophages, and PD-L1-expressing tumor cells and fibroblasts than in the BRCA1/2 wild-type setting. This evidence concerns the gene BRCA1 and neoplasm.